Contact Us
Drug Search Results
More Filters [+]

JSKN-016

Alternative Names: JSKN-016, JSKN 016, JSKN016
Latest Update: None
Latest Update Note: None

Product Description

JSKN016 is a bispecific antibody conjugated drug (ADC) targeting HER3 and TROP2, which is developed inhouse with proprietary Glycan-specific conjugation platform. JSKN016 can induce apoptosis of TROP2 or HER3 positive tumor cells, and penetrate the cell membrane into antigen-negative tumor cells to exert bystander effect, thus effectively inhibiting the growth of tumor cells. The clinical study of JSKN016 for the treatment of advanced malignant solid tumors has been accepted by the CDE. (Sourced from: https://www.alphamabonc.com/en/html/news/2549.html)

Mechanisms of Action: ERBB3 Inhibitor,TROP2 Inhibitor

Novel Mechanism: Yes

Modality: Antibody Drug Conjugate

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for JSKN-016

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CTR20241426

P1

Unknown

Oncology Solid Tumor Unspecified

None

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions